

Advancements in Pharmacovigilance: Enhancing Safety Drug Generation for Better Patient Outcomes

Prof. (Dr.)Mohd.Wasiullah^{1*}, Prof. (Dr.)Piyush Yadav², LecturerVikas Yadav^{3*},Asst. Prof. Mohit Vishwakarma⁴,Saurabh Shukla⁵

Date of Submission: 25-04-2025

Date of Acceptance: 05-05-2025

ABSTRACT

Pharmacovigilance (PV) is a critical discipline in modern healthcare, focused on ensuring the safety, efficacy, and tolerability of medicinal products throughout their lifecycle. The World Health Organization (WHO) defines PV as "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other possible drug-related problems." Historically, PV has evolved in response to public health tragedies, such as the thalidomide disaster, which highlighted the need for structured drug safety monitoring systems. The role of PV has expanded beyond post-marketing surveillance to encompass the entire drug development continuum, including pre-clinical studies, clinical trials, and post-authorization real-world monitoring. Regulatory agencies require pharmaceutical manufacturers to establish Risk Management Plans (RMPs) and Pharmacovigilance System Master Files (PSMFs) as part of the approval process. Emerging technologies, including artificial intelligence (AI), machine learning (ML), and blockchain, are transforming PV practices, enabling more efficient signal detection and data management. However, the integration of these technologies raises ethical and regulatory challenges, particularly concerning data privacy and algorithmic bias. The report aims to provide a comprehensive overview of the advancements in pharmacovigilance and their implications for safer drug generation. It will examine the evolution and foundational principles of PV, analyze the emerging technological tools reshaping pharmacovigilance, explore the role of real-world data and evidence in enhancing safety profiles, review global regulatory initiatives and harmonization efforts, and identify operational, ethical, and legal challenges in modern PV systems.

KEYWORD: Pharmacovigilance, Artificial Intelligence (AI) / Machine Learning (ML), Real-World Evidence (RWE), Regulatory

Harmonization, Adverse Drug Reactions (ADRs), Patient-Centered Safety.

I. INTRODUCTION

❖ Background and Evolution of Pharmacovigilance

Pharmacovigilance (PV) is the science of detecting, assessing, understanding, and preventing adverse effects or drug-related issues, as defined by the WHO. Its origin stems from medical tragedies like the thalidomide disaster, which revealed the need for systematic drug safety oversight. This led to the creation of regulatory bodies such as the FDA, EMA, and WHO's Programme for International Drug Monitoring (PIDM), with global databases like VigiBase and FAERS. Despite these advances, traditional PV systems face limitations like underreporting and delayed signal detection, highlighting the need for innovation—especially in fast-paced scenarios like the COVID-19 pandemic.

❖ Importance of Pharmacovigilance in Modern Drug Development

PV now plays a role across the drug lifecycle—from preclinical testing to post-market monitoring. The complexity of modern therapies (e.g., biologics, gene therapies) demands comprehensive safety oversight. Regulatory requirements such as Risk Management Plans (RMPs) reflect this evolution. As drugs are administered to broader and genetically diverse populations, new safety signals may emerge. PV informs clinical decision-making, policy development, and patient empowerment through tools like digital adverse event reporting platforms.

❖ Drivers of Innovation in Pharmacovigilance

Several factors drive PV innovation:

- **Accelerated Drug Approvals** reduce pre-market evaluation time, increasing post-marketing responsibilities.
- **Globalization** necessitates harmonized safety standards across diverse regions.

- **Digital Health** tools generate vast real-world data (RWD), enabling timely surveillance but also posing integration and privacy challenges.
- **Patient-Centered Care** encourages direct patient reporting, enhancing real-world safety understanding.

❖ **Emerging Technologies Transforming Pharmacovigilance**

Technological integration is revolutionizing PV:

- **AI and ML** assist in detecting safety signals, analyzing unstructured data, and reducing manual workload.
- **Blockchain** enhances data security, transparency, and global collaboration.
- **EHR Integration** supports near real-time monitoring and regulatory decision-making based on real-world evidence, as seen in initiatives like the FDA's Sentinel.

❖ **Ethical, Legal, and Regulatory Considerations**

While technology improves PV, it also raises concerns over data privacy, algorithmic bias, and disparities in global oversight. Regulatory bodies are adapting with updated guidelines (e.g., ICH E2E, CIOMS) promoting international collaboration and ethical governance.

❖ **Role of Stakeholders in Pharmacovigilance Innovation**

Stakeholders include regulators, the pharmaceutical industry, healthcare providers, patients, and tech developers. Each plays a role in reporting, analyzing, and acting on drug safety data.

❖ **Purpose of the Report**

This report aims to:

- Explore PV's evolution and guiding principles,
- Assess technological innovations,
- Examine the use of real-world evidence,
- Review global regulatory efforts,
- Address operational and ethical challenges in modern pharmacovigilance.

II. CONCEPTUAL FRAMEWORK OF PHARMACOVIGILANCE

❖ **Definition and Scope**

Pharmacovigilance (PV), as defined by the WHO, is the science and activities focused on detecting, assessing, understanding, and preventing adverse effects or other drug-related problems. Over time, its scope has broadened to include

medication errors, counterfeit drugs, drug interactions, lack of efficacy, and safety in vulnerable populations like children and the elderly. PV today is a multidisciplinary field combining clinical medicine, epidemiology, data science, and regulatory science, acting as a bridge between pharmaceutical development, regulatory compliance, and clinical practice.

❖ **Evolution and Historical Milestones**

PV evolved significantly following major drug safety crises. The thalidomide disaster (1957–1961) prompted the creation of structured PV systems, including the WHO's PIDM in 1968. Other pivotal events, such as liver damage from benoxaprofen and cardiovascular risks from rofecoxib (Vioxx), highlighted the insufficiency of pre-market trials and emphasized the importance of post-market surveillance.

❖ **Objectives and Functions**

The primary goals of PV are to detect new adverse reactions, monitor known risks, identify causative factors, assess incidence, and continuously evaluate the benefit–risk balance of drugs. Key functions include:

- **Signal detection** using safety databases,
- **Causality assessment** through structured methods (e.g., WHO-UMC, Naranjo scale),
- **Risk communication** to stakeholders, and
- **Regulatory actions** like label changes, recalls, or risk mitigation plans.

❖ **Pharmacovigilance Throughout the Drug Lifecycle**

PV spans all stages of a drug's lifecycle:

- **Pre-Clinical/Clinical Phases:** Early safety data is collected during Phase I–III trials, reported through documents like DSURs and PSURs.
- **Post-Marketing Surveillance:** Involves spontaneous reports, active monitoring, and real-world data to continually assess drug safety.
- **Risk Minimization:** Strategies like REMS in the U.S. and RMPs in Europe include measures such as prescriber education, restricted distribution, and patient monitoring.

❖ **Global Pharmacovigilance Ecosystem and Stakeholders**

PV is a globally coordinated effort involving:

- **Regulators** (e.g., FDA, EMA, PMDA),
- **International bodies** (WHO, ICH, CIOMS),

- **Pharmaceutical companies (MAHs),**
- **Healthcare providers,**
- **Patients**
- **Research institutions and CROs.**

A major challenge is achieving harmonized practices, especially in LMICs, where PV infrastructure is often limited.

❖ **Modern Classifications and Terminology**

PV terminology includes:

- **Adverse Drug Reaction (ADR) and Adverse Event (AE),**
- **Signals,** indicating potential causal links,
- **Benefit–Risk Evaluations,** which guide regulatory decisions.

Expanded concerns now include medication errors, drug interactions, lack of efficacy, and product quality issues, reflecting the evolving complexity of pharmacovigilance.

III. TECHNOLOGICAL ADVANCEMENTS IN PHARMACOVIGILANCE

Technological innovation has reshaped pharmacovigilance (PV) into a proactive, data-driven discipline. Tools like artificial intelligence (AI), machine learning (ML), natural language processing (NLP), big data analytics, and blockchain are transforming drug safety monitoring by enhancing accuracy, speed, and scalability in signal detection and case processing.

❖ **Artificial Intelligence and Machine Learning**

AI and ML streamline routine PV tasks, enable real-time analysis, and enhance signal detection from vast data sources including electronic health records (EHRs), spontaneous reports, and social media. Systems like the FDA Sentinel and EMA's DARWIN EU use AI for early signal identification. ML models—such as neural networks and decision trees—effectively predict adverse drug reactions (ADRs). IBM Watson has been applied to case triage, reducing manual workload.

❖ **Natural Language Processing (NLP)**

NLP extracts drug safety information from unstructured text like clinical notes, literature, and social media. Models like BERT and BioBERT have improved ADR detection, enabling automated literature surveillance and enriching signal data from patient-reported narratives.

❖ **Big Data and Real-World Evidence (RWE)**

Big data from EHRs, claims databases, registries, and mobile apps offer longitudinal safety insights beyond controlled trials. Real-world evidence (RWE) supports post-market safety evaluations and label updates. Regulatory bodies like the FDA and OHDSI promote standardized frameworks for RWD analysis.

❖ **Automation in Case Management**

Robotic process automation (RPA) improves individual case safety report (ICSR) handling, automating data entry, validation, coding (e.g., using MedDRA), and submission. End-to-end automation reduces operational costs and boosts compliance. Deloitte reports show cost savings up to 40% in high-volume settings.

❖ **Signal Detection Using Advanced Analytics**

Traditional disproportionality analysis is enhanced by AI-integrated analytics. These tools prioritize true safety signals and minimize false positives by merging spontaneous reports with RWE and literature-based evidence, improving decision-making and regulatory response.

❖ **Social Media and Digital Surveillance**

Social media and health forums offer real-time, user-generated data on ADRs. Initiatives like MedWatcher Social and WEB-RADR show the value of mining digital platforms for early signal detection. However, concerns about data validity, privacy, and demographic bias remain.

❖ **Blockchain for Data Integrity**

Blockchain ensures data traceability, transparency, and integrity in PV. Distributed ledgers enable secure ADR reporting and tamper-proof audit trails. Pilot projects in Europe and Asia are exploring its use, though broader adoption is still emerging.

❖ **Challenges and Limitations**

Key challenges include data inconsistency, regulatory uncertainty, ethical/privacy concerns, and lack of technical expertise. A balanced integration of technology with human oversight and regulatory guidance is vital for effective, ethical PV advancement.

IV. REGULATORY ADVANCEMENTS AND GLOBAL HARMONIZATION IN PHARMACOVIGILANCE

Regulatory frameworks are essential to pharmacovigilance (PV), ensuring drug safety through standard-setting, compliance, and surveillance. Over the last two decades, global collaboration has increased, with harmonized guidelines and structured tools such as Risk Management Plans (RMPs) and Periodic Safety Update Reports (PSURs) enhancing consistency, transparency, and patient protection.

❖ Evolution of Regulatory Frameworks

PV regulation has shifted from national models to internationally aligned systems. Agencies like the EMA, FDA, PMDA (Japan), and CDSCO (India) now integrate pre- and post-marketing surveillance. A key example is the EU's 2012 PV legislation, which established mandatory frameworks for risk management and public engagement.

❖ Role of ICH in Harmonization

The International Council for Harmonisation (ICH) develops globally recognized PV guidelines:

- **ICH E2E:** Pharmacovigilance planning
- **ICH E2C (R2):** Periodic Benefit-Risk Evaluation Reports (PBRERs)
- **ICH E2D:** Post-marketing safety data
- **ICH E2B (R3):** Electronic case safety report transmission

These standards unify definitions, data formats, and procedures, easing global regulatory compliance and drug distribution.

❖ Risk Management Plans and REMS

Modern PV emphasizes risk minimization through:

- RMPs (EU) and REMS (U.S.), which outline known risks, mitigation strategies, and post-market commitments.

Guidance is provided by EMA's GVP Module V and the FDA's REMS regulations. Case Example: Isotretinoin (Accutane) in the U.S. requires REMS to manage teratogenic risk, including prescriber certification and patient consent.

❖ Periodic Safety Reporting

PSURs and PBRERs, mandated by regulators globally, provide structured safety updates that evaluate emerging risks and benefit–

risk balance. These tools help regulators and marketing authorization holders (MAHs) make evidence-based decisions regarding product safety and labeling (ICH E2C(R2), 2012).

❖ Global PV Programs and Databases

Key initiatives supporting global PV collaboration include:

- WHO PIDM and VigiBase (Uppsala Monitoring Centre)
- FDA Sentinel Initiative
- EMA's EudraVigilance
- Japan's MID-NET

These platforms enable data sharing, signal detection, and regulatory alignment across regions.

❖ Stakeholder and Public Engagement

Transparency and stakeholder involvement are emphasized through:

- Public access to RMPs and safety dashboards (e.g., FDA FAERS)
- Direct ADR reporting via MedWatch (U.S.), Yellow Card (UK), and PvPI (India)

These initiatives promote trust and enhance safety signal detection from real-world users.

❖ Challenges in Harmonization

Barriers to harmonization include:

- Variations in regulation and resources
- Data privacy issues (e.g., GDPR)
- Infrastructure gaps in LMICs
- Unequal digital adoption

WHO and ICH are addressing these challenges through global capacity-building and technical support programs.

V. REAL-WORLD EVIDENCE AND PATIENT CENTERED PHARMACOVIGILANCE

Traditional pharmacovigilance (PV), dependent on randomized controlled trials (RCTs) and spontaneous reporting, often fails to capture long-term or population-specific adverse drug reactions (ADRs). Real-World Evidence (RWE) and patient-centered approaches have emerged to bridge these gaps by leveraging real-world data (RWD) and direct patient input to enhance drug safety monitoring.

❖ Real-World Evidence in Pharmacovigilance

RWE is derived from real-world data sources such as:

- Electronic Health Records (EHRs)
- Insurance claims and billing data
- Disease registries
- Mobile health apps and wearables

Unlike RCTs, RWE includes diverse populations and real-life clinical scenarios. Regulatory bodies like the FDA and EMA endorse RWE as a critical supplement to traditional safety assessments, particularly in the post-marketing phase.

❖ Benefits of RWE in Pharmacovigilance

RWE enables:

- **Detection of Long-Term and Rare ADRs:** Supports extended follow-ups in populations underrepresented in RCTs.
- **Real-Time Safety Monitoring:** Systems like the FDA's Sentinel Initiative use linked EHRs and claims data for rapid signal detection.
- **Regulatory Action:** RWE has influenced drug label changes and usage restrictions.

Example: Cardiovascular risks linked to rosiglitazone were identified through insurer data, prompting regulatory intervention.

❖ Patient-Centered Pharmacovigilance

Patient-centered PV integrates the patient's voice into safety evaluations:

- **Direct Reporting:** Platforms like MedWatch (U.S.), EudraVigilance (EU), and PvPI (India) allow patients to report ADRs.
- **Patient-Reported Outcome Measures (PROMs):** These tools capture symptoms, quality of life, and treatment burden directly from patients.
- **Digital Apps:** Applications such as WEB-RADR and MedWatcher enable real-time ADR submission and feedback. Studies show patient-reported data often highlight different and more severe experiences than clinician reports.

❖ Social Media and Patient Forums

Social media platforms, online forums, and patient blogs serve as unconventional yet valuable sources for drug safety data. These channels can identify:

- Emerging ADRs
- Off-label drug use

- Patient-reported challenges

AI and NLP technologies are used to analyze massive amounts of text data to detect safety signals. Despite their benefits, such platforms raise concerns about data quality, misinformation, and user privacy.

❖ Limitations and Considerations

Challenges in implementing RWE and patient-centered PV include:

- **Data Quality Issues:** EHRs and patient reports may be incomplete or inconsistent.
- **Observational Bias:** RWE lacks the control of RCTs, making causality assessment more difficult.
- **Regulatory Scrutiny:** Acceptance of RWE requires adherence to rigorous methodological standards.
- **Digital Inequities:** Not all patients have access to or literacy in digital tools.

Efforts are ongoing to develop regulatory frameworks to ensure the responsible and equitable use of RWD in pharmacovigilance.

VI. FUTURE PERSPECTIVES AND CHALLENGES IN PHARMACOVIGILANCE

Pharmacovigilance (PV) is transitioning from passive surveillance to proactive, predictive systems. With AI, global data integration, and patient-centric tools, the future of PV lies in personalized safety monitoring and seamless integration within healthcare systems. However, these advancements also bring new challenges in data management, ethics, regulation, and equity.

❖ Future Directions in Pharmacovigilance

• AI and Machine Learning

Artificial intelligence (AI) and machine learning (ML) are revolutionizing signal detection by automating case reviews, extracting ADRs from unstructured data, and predicting emerging risks. Tools like IBM Watson and DeepMind enhance accuracy and reduce manual workload.

• Personalized Pharmacovigilance

Pharmacogenomics is enabling tailored drug safety by linking genetic profiles to ADR risks. For example, screening for HLA-B*15:02 helps prevent carbamazepine-induced reactions in certain populations.

- **Global Data Integration**

Efforts like ICH E2B(R3), HL7 FHIR, and WHO's VigiBase aim to standardize PV data formats and facilitate cross-border sharing. Challenges include data privacy laws like GDPR and system interoperability.

- **Enhanced Patient Engagement**

Future PV systems will offer real-time, bidirectional communication. Apps like MedSafety and WEB-RADR 2 provide alerts and personalized safety updates, improving patient participation in drug monitoring.

- ❖ **Challenges and Risks**

- **Data Overload**

The influx of diverse data—EHRs, wearables, social media—risks overwhelming systems. Effective filtering and validated AI tools are essential to manage true signals versus noise.

- **Data Quality and Standardization**

Incomplete or inconsistent real-world data can undermine reliability. Variations in medical terminologies hinder harmonization and automated analysis.

- **Regulatory Lag**

Innovation in PV often outpaces regulatory adaptation. Agencies struggle to evaluate AI-derived insights, RWE, and patient-reported outcomes without formalized guidelines.

- **Ethical and Privacy Concerns**

AI and digital tools raise concerns over data privacy, algorithmic bias, and informed consent. Ethical governance is needed to protect patient autonomy and equity.

- **Global Inequities**

Low- and middle-income countries face infrastructure and capacity gaps, leading to underreporting and delayed signal detection. Investment in PV capacity is essential for global equity.

- **Integration into Clinical Practice**

Even with advanced tools, underreporting persists due to workflow disruptions, lack of clinician incentives, and poor app design.

- **Public Trust and Misinformation**

Digital platforms can spread unverified safety claims. Transparent, timely communication

is critical to counter misinformation and maintain trust.

- **Cost and Resource Constraints**

High costs of AI tools, pharmacogenomics, and real-time systems limit adoption, especially in public sectors. Strategic investments and policies are needed for sustainable advancement.

VII. CONCLUSION

Pharmacovigilance has become an indispensable pillar of modern healthcare, ensuring that the benefits of medicines continue to outweigh their risks in real-world use. Through the integration of digital technologies, artificial intelligence, and real-world evidence, pharmacovigilance systems have transitioned from passive reporting mechanisms to dynamic, predictive tools capable of safeguarding patient health more effectively than ever before. Regulatory bodies and global collaborations have played a vital role in harmonizing efforts, while patient engagement has brought greater transparency and responsiveness to safety monitoring. Despite these advancements, challenges such as data quality variability, ethical concerns, infrastructure disparities, and regulatory lag continue to hinder optimal implementation. However, the path forward is promising. With sustained investment, policy innovation, and global cooperation, pharmacovigilance is well-positioned to support the safe and responsible development of medicines—ultimately leading to better patient outcomes and stronger public trust in healthcare systems.

REFERENCE:

- [1]. Uppsala Monitoring Centre. (2022). The story of pharmacovigilance. WHO Collaborating Centre for International Drug Monitoring. Retrieved from <https://www.who-umc.org/>
- [2]. Strom, B. L., Kimmel, S. E., & Hennessy, S. (Eds.). (2019). *Pharmacoepidemiology* (6th ed.). Wiley-Blackwell.
- [3]. vanPuijenbroek, E., & Hoes, A. W. (2009). Pharmacovigilance in the era of drug regulation. *European Journal of Clinical Pharmacology*, 65(10), 1021–1025. <https://doi.org/10.1007/s00228-009-0784-2>
- [4]. World Health Organization. (2002). *The Importance of Pharmacovigilance: Safety*

- Monitoring of Medicinal Products. World Health Organization.
- [5]. Beninger, P. G. (2018). Pharmacovigilance: An overview. *Clinical Therapeutics*, 40(12), 1995–2002. <https://doi.org/10.1016/j.clinthera.2018.10.004>
- [6]. Hazell, L., &Shakir, S. A. (2006). Under-reporting of adverse drug reactions: A systematic review. *Drug Safety*, 29(5), 385–396. <https://doi.org/10.2165/00002018-200629050-00002>
- [7]. Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012). Novel data-mining methodologies for adverse drug event discovery and analysis. *Clinical Pharmacology & Therapeutics*, 91(6), 1010–1021. <https://doi.org/10.1038/clpt.2012.61>
- [8]. De Clercq, E., Vlieghe, E., &Devriendt, H. (2020). AI in pharmacovigilance: Smart safety. *Drug Discovery Today*, 25(9), 1573–1577. <https://doi.org/10.1016/j.drudis.2020.06.004>
- [9]. Finkelstein, J. A., &Durr, A. (2011). Pharmacovigilance and safety in an era of personalized medicine. *American Journal of Public Health*, 101(10), 1799–1804. <https://doi.org/10.2105/AJPH.2011.300279>
- [10]. Shoaib, M., & Babar, Z. U. D. (2021). Artificial intelligence in pharmacovigilance: A narrative review. *Journal of Clinical Medicine*, 10(9), 2061. <https://doi.org/10.3390/jcm10092061>
- [11]. Corrigan-Curay, J., Sacks, L., & Woodcock, J. (2018). Real-world evidence and real-world data for evaluating drug safety and effectiveness. *JAMA*, 320(9), 867–868. <https://doi.org/10.1001/jama.2018.9444>
- [12]. Makady, A., de Boer, A., Hillege, H., Klungel, O., &Goettsch, W. (2017). What is real-world data? A review of definitions based on literature and stakeholder interviews. *Value in Health*, 20(7), 858–865. <https://doi.org/10.1016/j.jval.2017.02.018>
- [13]. Sultana, J., et al. (2020). Pharmacovigilance and real-world evidence: Current trends and future directions. *Clinical Therapeutics*, 42(2), 349–359. <https://doi.org/10.1016/j.clinthera.2020.01.017>
- [14]. Wilkins, J. R., & Brinker, A. (2021). Advancements in real-world data analysis for drug safety monitoring. *Pharmacoepidemiology and Drug Safety*, 30(1), 17–27. <https://doi.org/10.1002/pds.5199>
- [15]. Eichler, H. G., Pignatti, F., Flamion, B., Leufkens, H., & Breckenridge, A. (2008). Balancing early market access to new drugs with the need for benefit/risk data: A mounting dilemma. *Nature Reviews Drug Discovery*, 7(10), 818–826. <https://doi.org/10.1038/nrd2665>
- [16]. Wiktorowicz, M. E., De Laat, S., Gaebel, W., et al. (2012). An international policy perspective on pharmacovigilance: The challenge of balancing patient safety and public health. *Health Policy*, 105(3), 217–226. <https://doi.org/10.1016/j.healthpol.2011.12.012>
- [17]. Alvaro, S., & Peterson, L. A. (2019). The role of international collaborations in global pharmacovigilance. *Global Health Action*, 12(1), 1601785. <https://doi.org/10.1080/16549716.2019.1601785>
- [18]. Angell, M., & Kassirer, J. P. (2002). Drug companies and doctors: A story of corruption. *The New York Review of Books*, 49(12), 60–67.
- [19]. Giezen, T. J., Mantel-Teeuwisse, A. K., &Leufkens, H. G. (2009). Pharmacovigilance of biopharmaceuticals: Challenges remain. *Drug Safety*, 32(10), 811–817. <https://doi.org/10.2165/11319660-000000000-00000>
- [20]. Davis, C., & Abraham, J. (2013). *Unhealthy pharmaceutical regulation: Innovation, politics and promissory science*. Palgrave Macmillan.
- [21]. Senger, A. K., & Weiner, G. (2020). The evolving landscape of pharmacovigilance: Emerging trends and challenges. *Journal of Clinical Pharmacology*, 60(8), 1017–1028. <https://doi.org/10.1002/jcph.1505>
- [22]. Bero, L. A., & Rennie, D. (2007). Editorial peer review: A process for progress. *JAMA*, 298(3), 314–317. <https://doi.org/10.1001/jama.298.3.314>



- [23]. Cohen, A. L., & Slater, J. (2018). The pharmaceutical industry and its complex relationships with stakeholders. *Pharmaceutical Economics*, 36(8), 1078–1091. <https://doi.org/10.1097/PEC.0000000000000722>
- [24]. Bessell, T. L., & Rogers, S. (2019). Global pharmacovigilance and the role of public health surveillance. *Global Public Health*, 14(5), 705–719. <https://doi.org/10.1080/17441692.2018.1502080>
- [25]. Liu, L., & Zhang, T. (2020). Evaluation of drug safety using big data: A review of the advances. *Journal of Pharmacovigilance*, 35(2), 118–127. <https://doi.org/10.1016/j.jpharm.2020.03.008>
- [26]. Jackson, G. R., & Stone, M. (2017). Understanding pharmacovigilance databases and their role in drug safety. *Pharmacoepidemiology and Drug Safety*, 26(11), 1232–1239. <https://doi.org/10.1002/pds.4248>
- [27]. Raftery, J., & Hayward, S. (2021). Improving pharmacovigilance through real-time monitoring of drug safety. *Drug Safety*, 44(6), 1113–1122. <https://doi.org/10.1007/s40264-021-01096-1>
- [28]. García-Sánchez, J., & Sánchez, M. (2021). Challenges in drug safety and pharmacovigilance: A systematic review of clinical trials. *Drug Safety*, 43(4), 441–453. <https://doi.org/10.1007/s40264-021-01092-5>
- [29]. Choi, J., & Jung, H. (2019). Artificial intelligence applications in pharmacovigilance and regulatory affairs: A future perspective. *Journal of Regulatory Science*, 7(2), 85–92. <https://doi.org/10.1002/jrs.2356>
- [30]. Parker, J., & Mackenzie, D. (2020). Evaluating the global impact of pharmacovigilance: Insights from recent studies. *Journal of Clinical Research*, 49(2), 113–122. <https://doi.org/10.1002/jcr.217>
- [31]. McNeill, R., & Bates, D. (2018). Real-world evidence in clinical pharmacovigilance: An emerging strategy for assessing drug safety. *European Journal of Clinical Pharmacology*, 74(9), 1249–1257. <https://doi.org/10.1007/s00228-018-2471-9>